SERIES B PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd.Enlivex Therapeutics Ltd. • May 29th, 2024 • Pharmaceutical preparations
THIS SERIES B PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on the earlier of (i) May 27, 2029 and (ii) the 60th day following the date on which the Company publicly announces the occurrence of the Series B Milestone Event (the earlier of such dates, the “Termination Date”), but not thereafter, to subscribe for and purchase from Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), up to ______ of the Company’s ordinary shares, NIS 0.40 per share (“Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to th
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 29th, 2024 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 27, 2024, between Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
